Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas

ReutersMay 4, 2026 11:36 AM

View all comments（0）



May 4 (Reuters) - Palvella Therapeutics Inc PVLA.O:

PALVELLA THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2 LOTU TRIAL OF FAST TRACK-DESIGNATED QTORIN™ RAPAMYCIN FOR CLINICALLY SIGNIFICANT ANGIOKERATOMAS
PALVELLA THERAPEUTICS INC - TOPLINE RESULTS FROM PHASE 2 LOTU TRIAL EXPECTED IN SECOND HALF OF 2027

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Today’s Market Recap: Tech-Led Rally Drives Record Highs as Trump Arrives in Beijing

Tech-driven gains pushed the S&P 500 and Nasdaq to record highs as President Trump arrived in Beijing alongside Nvidia's CEO. Despite surging PPI data fueling rate-hike fears, strong AI-related growth from Cisco and Alibaba, plus Cerebras Systems' massive IPO demand, sustained investor optimism acro

Anthropic in Talks for Massive $30 Billion Funding, Valuation May Join Trillion-Dollar Ranks

TradingKey - On May 12, Eastern Time, Bloomberg reported that AI startup Anthropic is in preliminary discussions with investors to raise at least $30 billion in new capital at a pre-money valuation exceeding $900 billion. If the deal is finalized, it would mark the company's largest funding round to

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

Palantir Stock Forecast: Is a Trillion-Dollar Market Cap for PLTR Stock Achievable by 2030?

Whether Palantir reaches the trillion-dollar level will depend on whether it can maintain its technological lead and successfully make the transition from a U.S.-centered powerhouse to a global AI utility.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools